Folger Nolan Fleming Douglas Capital Management Inc. lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 0.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,576 shares of the medical instruments supplier’s stock after selling 403 shares during the period. Becton, Dickinson and accounts for approximately 1.5% of Folger Nolan Fleming Douglas Capital Management Inc.’s holdings, making the stock its 17th biggest position. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Becton, Dickinson and were worth $11,236,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in BDX. HB Wealth Management LLC increased its position in Becton, Dickinson and by 12.8% in the 2nd quarter. HB Wealth Management LLC now owns 14,936 shares of the medical instruments supplier’s stock worth $3,682,000 after buying an additional 1,690 shares during the period. Ritholtz Wealth Management grew its stake in Becton, Dickinson and by 20.3% in the second quarter. Ritholtz Wealth Management now owns 1,905 shares of the medical instruments supplier’s stock valued at $470,000 after acquiring an additional 321 shares during the period. YorkBridge Wealth Partners LLC boosted its position in shares of Becton, Dickinson and by 7.1% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,923 shares of the medical instruments supplier’s stock worth $967,000 after buying an additional 259 shares during the period. PDS Planning Inc boosted its position in Becton, Dickinson and by 23.8% during the second quarter. PDS Planning Inc now owns 1,182 shares of the medical instruments supplier’s stock valued at $291,000 after purchasing an additional 227 shares during the last quarter. Finally, IFM Investors Pty Ltd boosted its position in Becton, Dickinson and by 5.3% during the second quarter. IFM Investors Pty Ltd now owns 47,938 shares of the medical instruments supplier’s stock valued at $11,818,000 after purchasing an additional 2,427 shares during the last quarter. 86.74% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on BDX. Morgan Stanley reduced their price target on Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. Stifel Nicolaus decreased their target price on Becton, Dickinson and from $290.00 to $280.00 in a research report on Monday, July 18th. The Goldman Sachs Group lifted their price target on Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research note on Tuesday, August 16th. Wells Fargo & Company upgraded Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 price target for the company in a research note on Friday, June 24th. Finally, Citigroup downgraded Becton, Dickinson and from a “neutral” rating to a “sell” rating and cut their target price for the stock from $265.00 to $235.00 in a research note on Monday, July 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $277.63.
Insider Buying and Selling at Becton, Dickinson and
Becton, Dickinson and Price Performance
NYSE:BDX traded down $6.24 during midday trading on Friday, hitting $230.95. The company had a trading volume of 62,499 shares, compared to its average volume of 968,418. The stock’s fifty day moving average price is $252.37 and its 200-day moving average price is $253.93. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.58. Becton, Dickinson and Company has a 52-week low of $231.46 and a 52-week high of $280.62. The company has a market capitalization of $65.87 billion, a PE ratio of 40.89, a P/E/G ratio of 3.12 and a beta of 0.57.
Becton, Dickinson and (NYSE:BDX – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The company had revenue of $4.64 billion during the quarter, compared to the consensus estimate of $4.47 billion. During the same period in the prior year, the firm earned $2.74 earnings per share. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. As a group, research analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.
Becton, Dickinson and Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, September 30th. Investors of record on Friday, September 9th will be paid a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 dividend on an annualized basis and a dividend yield of 1.51%. Becton, Dickinson and’s dividend payout ratio is presently 60.00%.
About Becton, Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.